AG-236 for polycythemia vera
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a new medicine called AG-236 in people with polycythemia vera (PV), a condition where the body makes too many red blood cells. The trial aims to see if AG-236 can reduce the need for phlebotomies (removing blood to lower red blood cell count) and help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of polycythemia vera (PV) based on standard criteria.
- You need to have had at least 3 blood removal procedures (phlebotomies) in the past 6 months, or at least 5 in the past 12 months, and at least 1 in the last 3 months.
- If you are on blood-thinning or other PV treatments, your dose must be stable for at least 2 months (or 6 months for interferons) before starting the trial.
- You must not have used certain other experimental treatments recently, like GalNAc-targeting products or hepcidin mimetics.
- You cannot have had a blood clot within the last 2 months, and you must not have other serious uncontrolled liver, kidney, heart, or lung conditions.
- If you have had cancer, it must have been treated and not come back, except for certain minor skin cancers or early-stage cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called sapablursen for people with polycythemia vera who still need frequent phlebotomies. The goal is to see if the drug can reduce the need for blood removal and help control the disease safely.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This study is testing a medicine called ropeginterferon alfa-2b for people with polycythemia vera (a blood condition) who do not have a swollen spleen that causes symptoms. It looks at how well the medicine works and how it affects your daily life through simple questionnaires.
This study tests an injection called BEBT-507 for people with polycythemia vera (a blood condition that makes too many red blood cells). It's for those who haven't responded well to or can't tolerate standard treatments like hydroxyurea or interferon. The goal is to see if this new drug can help control the disease.
This trial tests a medicine called peginterferon for people with two blood disorders: essential thrombocythemia (too many platelets) and polycythemia vera (too many red blood cells). The goal is to see if peginterferon can help control these conditions and is safe.
This trial tests a new drug called rusfertide for adults with polycythemia vera whose red blood cell levels are not well controlled. The drug is given as an injection and may help reduce the need for phlebotomy (blood removal) and manage symptoms.
Hear when a new Polycythemia Vera trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.